Theralase Technologies Inc.
TSX VENTURE : TLT
OTC Bulletin Board : TLTFF

Theralase Technologies Inc.

November 03, 2006 11:44 ET

Theralase Technologies Inc. Announces Management Team Appointments

TORONTO, ONTARIO--(CCNMatthews - Nov. 3, 2006) - Theralase Technologies Inc. (TSX VENTURE:TLT)(OTCBB:TLTFF) announces the appointment of David M. Groves, B.A. as President of its World Trade Division. Mr. Groves is a senior sales and marketing professional with over 30 years experience selling products and services to the healthcare and financial markets. Mr. Groves will be responsible for international sales and business development of the Theralase product line, leading a 4 member internal sales team and also a 40 member external manufacturing representative team to sell the Theralase product line into the Canadian and US medical marketplace.

Theralase Technologies Inc. announces the appointment of Mr. Anselm Viswasam, P. Eng., MBA as Production Manager and Research and Development Manager. Mr. Viswasam is a senior engineering professional with over 10 years experience in managing high volume production lines and launching high technology products. Mr. Viswasam will be responsible for managing all aspects of Theralase's expanding TLC-1000 production requirements and also the launch of Theralase's patented biofeedback technology in 2007. Theralase's patented biofeedback technology sets a new standard in the therapeutic laser marketplace by introducing technology that is able to precisely target tissue with an exact dosage of energy; hence, dramatically improving the efficacy of patient based treatments. Mr. Viswasam leads a 4 member technical team in an ISO-13485 certified design and manufacturing facility in the completion of his assignments.

Roger White, President and CEO of Theralase Technologies Inc., is pleased to welcome Mr. Groves and Mr. Viswasam to the management team and believes that these new appointments support the corporate mandate of accelerating the revenue growth and profitability of the corporation.

Theralase Technologies Inc. designs, develops, manufactures and sells leading edge, proprietary, high powered, super-pulsed therapeutic laser equipment employed in a wide range of biostimulative medical therapy applications. The Theralase technology platform targets several diverse healthcare sectors -- firstly, for non-invasive pain management, control and therapy, including a wide range of neural-musculo-skeletal conditions, arthritic and rheumatologic disorders -- secondly, to bio-stimulate and accelerate wound care and healing, including: bone fracture regeneration and osteoarthritic conditions -- and thirdly, combining proprietary metallic complexes with photo-dynamic lasers to attack specifically-targeted cancerous growths. For a complete profile of Theralase Technologies Inc. and its products visit www.theralase.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the contents of this release.

Contact Information